dr reddys quarterly -- does not say much

Segmental Analysis

Global Generics

Revenues from Global Generics segment are at ?16.1 billion
Does not say much about fonda

http://www.drreddys.com/media/popups/oct25_2011_q2fy12.html


($329 million) in Q2 FY12 registering growth of 18% over previous year.

Revenues from North America at ?6.3 billion in Q2 FY12 versus ?4.4 billion in Q2 FY11. Growth in USD terms of 45% was led by new product launches in the last twelve months and market share improvement in key products.
5 new products launched during the quarter, including limited competition products such as fondaparinux and fexofenadine pseudoephedrine D24 OTC.
24 products of our prescription portfolio feature among the Top 3 rank in market share (Source: IMS Sales Volumes July 2011).
During the quarter, 4 ANDAs were filed. The cumulative ANDA filings as of 30th September, 2011 are 177. A total of 76 ANDAs are pending for approval with the USFDA of which 40 are Para IVs and 11 are FTFs.